PBLS Parabilis Medicines, Inc.

Executive Summary

Parabilis Medicines is a pre-IPO biotech filing an amended S-1 registration statement, disclosing a major License and Collaboration Agreement with Regeneron Pharmaceuticals entered into on May 15, 2026. Regeneron pays a $50M upfront cash payment and commits to a $75M equity investment in the IPO, plus significant downstream development and sales milestones and tiered royalties on net sales. The filing also establishes the 2026 equity incentive plan and standard director indemnification agreements.

Actionable Insight

Key Facts

• Regeneron pays a $50,000,000 non-refundable upfront cash payment to Parabilis within [***] of the Effective Date (May 15, 2026).
• Regeneron commits to a $75,000,000 equity investment in Parabilis via a side letter tied to the IPO.
• Parabilis grants Regeneron an exclusive, worldwide, royalty-bearing license under Parabilis Technology to develop, manufacture, commercialize and exploit Licensed Products in the Field.
• The collaboration targets multiple collaboration targets under Research Plans for the Parabilis platform (Helicon-conjugated Antibodies).
• Regeneron has sole decision-making authority over all clinical development, regulatory filings, manufacturing, and commercialization of Licensed Products.
• The agreement includes development milestone payments (per Collaboration Target and per Licensed Product) and sales milestone payments (up to [***] per Licensed Product).
• Royalties on net sales are tiered (low-to-high single-digit percentages) on aggregate annual Net Sales in the Territory, with tiers between >$0 and <$[***] up to >=$[***].
• The S-1/A does not specify the number of shares or proposed price range for the IPO (both placeholders).
• Parabilis has applied to list on Nasdaq Global Market under the symbol 'PBLS'.
• The company is an 'emerging growth company' and 'smaller reporting company'.

Financial Impact

$50M upfront cash + $75M equity investment from Regeneron; plus unknown development milestones, sales milestones up to [***] per product, and tiered royalties on net sales. Revenue and net income figures from Parabilis' financial statements are not in the provided filing documents.

Risk Factors

• IPO pricing still undisclosed -- no public market for the stock yet; execution risk on the offering remains.
• All development and commercialization decisions rest solely with Regeneron, leaving Parabilis as a passive partner with no control over pipeline progression or commercial strategy.
• Regeneron can terminate the agreement on a collaboration-target basis with [***] prior written notice, or on a Licensed Product basis with [***] prior written notice.
• If Parabilis materially breaches, Regeneron can reduce royalties by [***] and terminate Commercially Reasonable Efforts obligations as a remedy.
• Confidential deal terms (milestone amounts, royalty rates, target numbers) are redacted, making precise valuation impossible pre-IPO.

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

US Market Status

Related Tickers